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Endometrial cancer is the most common gynecologic malignancy in the United States
but it remains poorly understood at the molecular level. This investigation was conducted
to specifically assess whether gene expression changes underlie the clinical and patho-
logic factors traditionally used for determining treatment regimens in women with stage I
endometrial cancer.These include the effect of tumor grade, depth of myometrial invasion
and histotype. We utilized oligonucleotide microarrays to assess the transcript expres-
sion profile in epithelial glandular cells laser microdissected from 79 endometrioid and 12
serous stage I endometrial cancers with a heterogeneous distribution of grade and depth of
myometrial invasion, along with 12 normal post-menopausal endometrial samples. Unsu-
pervised multidimensional scaling analyses revealed that serous and endometrioid stage
I cancers have similar transcript expression patterns when compared to normal controls
where 900 transcripts were identified to be differentially expressed by at least fourfold (uni-
variate t -test, p<0.001) between the cancers and normal endometrium.This analysis also
identified transcript expression differences between serous and endometrioid cancers and
tumor grade, but no apparent differences were identified as a function of depth of myome-
trial invasion. Four genes were validated by quantitative PCR on an independent set of
cancer and normal endometrium samples.These findings indicate that unique gene expres-
sion profiles are associated with histologic type and grade, but not myometrial invasion
among early stage endometrial cancers. These data provide a comprehensive perspective
on the molecular alterations associated with stage I endometrial cancer, particularly those
subtypes that have the worst prognosis.
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INTRODUCTION
The majority of endometrial malignancies are carcinomas, which
historically have been characterized as Type I or Type II on
the basis of both clinical presentation as well as histopathologic
variables (Deligdisch and Holinka, 1987). Based on these cri-
teria, Type I endometrial carcinomas are usually endometrioid
in histology, present with early stage disease at diagnosis, are
well-differentiated with respect to grade, and are often associ-
ated with a hyper-estrogenic milieu (Berchuck and Boyd, 1995).
These cancers display a high incidence of loss of function alter-
ations in the PTEN tumor suppressor gene as well as defects
in DNA mismatch repair resulting in microsatellite instability
(Risinger et al., 1993, 1997; Tashiro et al., 1997). Endometrioid
tumors may also contain activating mutations of the CTNNB1,
PIK3CA, and PIK3R1 genes, and more infrequently KRAS2 and
FGFR2 genes (Ignar-Trowbridge et al., 1992; Fukuchi et al., 1998;
Kobayashi et al., 1999; Oda et al., 2005; Hayes et al., 2006; Pol-
lock et al., 2007). In contrast, Type II endometrial cancers usually
have non-endometrioid histology, are poorly differentiated, and
are frequently advanced stage at the time of diagnosis (Berchuck
and Boyd, 1995). These tumors are more likely to harbor TP53
mutation, and are characterized by widespread aneuploidy (Lukes
et al., 1994; Berchuck and Boyd, 1995; Kohler et al., 1995, 1996).
Type II lesions infrequently display the molecular alterations com-
monly associated with type I endometrioid tumors. However, the
definition of Type I and Type II is imprecise particularly when high
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grade endometrioid cancers are considered, suggesting that more
heterogeneity exists than the present dichotomous classification
model (Risinger et al., 2003; Ferguson et al., 2004, 2005; Maxwell
et al., 2005). Recent comprehensive genomic mutational portraits
of endometrial cancer will likely aid in development of more pre-
cise classification models of uterine cancers (Kuhn et al., 2012; Le
Gallo et al., 2012; Liang et al., 2012).
Transcript expression investigations by hybridization-based
microarray techniques have previously demonstrated that distinct
profiles are associated with different histologic types of endome-
trial cancer (Moreno-Bueno et al., 2003; Risinger et al., 2003; Cao
et al., 2004; Ferguson et al., 2004, 2005; Maxwell et al., 2005).
Although these studies revealed differentially expressed transcripts
amongst endometrial cancer histotypes, there are limited data
associated with these subtypes of cancer when compared to normal
post-menopausal endometrial epithelium, the presumptive cell of
origin for this disease. Previous studies have not been specifically
designed to examine transcript expression profiles as a function of
sub-stage or grade, hence a focused evaluation of early endometrial
cancer and traditionally used clinicopathologic criteria is lacking
(Mutter et al., 2001; Saidi et al., 2004; Wong et al., 2007). We exam-
ined the hypothesis that transcript expression profiles underlie
the basic clinicopathologic variables currently used to character-
ize this disease. A greater understanding of distinct gene expression
patterns of early endometrial carcinogenesis could result in identi-
fication of potential targets for future prognostic, therapeutic, and
chemopreventive agents.
MATERIALS AND METHODS
TISSUE SPECIMENS
Stage I endometrial cancers utilized for this study were collected
from patients (following counseling and written consent) that
enrolled on one of two different protocols: (1) a tissue and data
collection protocol approved by the Institutional Review Board
(IRB) at Duke University Medical Center; and (2) a tissue and
data collection protocol (GOG-136) managed by the Gynecologic
Oncology Group which was approved by the IRB of each institu-
tion that provided specimens to the central repository. The current
project used a de-identified sample set of specimens and data from
these two resources after approvals from the Duke University IRB
and the GOG Protocol Committee. Second level review was pro-
vided by the Office of Human Protections at the U.S. Medical
Research and Material Command. An ethics committee review
was not required to review based on the proposed research efforts.
Hematoxylin and eosin stained tissue specimens were evalu-
ated by one of two board certified gynecologic pathologists (CZ
and who else?) to confirm the original diagnosis. Only homoge-
nous serous endometrial cancers were used for the analysis and
mixed epithelial cancers were excluded. Normal endometrial sam-
ples obtained from hysterectomy specimens from 12 age-matched
post-menopausal women were used for the comparison.
For the discovery analysis, samples differed by grade and stage
as follows: 9 IAG1, 14 IAG2, 7 IAG3, 14 IBG1, 12 IBG2, 12 IBG3,
7 ICG1, 10 ICG2, and 6 ICG3. There were 79 endometrioid
and 12 serous cancers. Sub-stage designations were based on the
1988 version of FIGO classifications of disease that more clearly
describe the extent of invasion and thus allow for comparison of
non-invading versus deep invading tumors as compared to the
revised 2010 criteria.
Additionally,array data from six pre-menopausal endometrium
samples (three proliferative and three secretory phase of the men-
strual cycle) were compared to the array data from the 91 stage I
cancers to assess whether ontology of differentially expressed genes
varied substantially with the menopausal status of the control
endometrium.
An independent set of cases used for validation of discovery
gene expression data included 40 stage I endometrioid endome-
trial cancers, 18 stage I serous endometrial cancers, 7 normal
post-menopausal endometrial samples, and 18 pre-menopausal
endometrial (n= 9 proliferative phase and n= 9 secretory phase)
samples.
TISSUE PREPARATION
Laser microdissection was used to isolate cancer cells from tumors
or epithelial cells from normal endometrium. Approximately 10–
15 serial tissue thin sections (8µm) for each cancer case and up to
40 serial tissue thin sections for each normal control were required
to obtain sufficient RNA. Laser microdissection enabled collection
of greater than 95% purity of cancer or normal epithelial cells.
OLIGONUCLEOTIDE MICROARRAYS
Approximately 50 ng of total RNA was extracted from each sam-
ple and processed using the GeneChip two-cycle cDNA synthesis
kit (Affymetrix Inc., Santa Clara, CA, USA). Approximately 10µg
of amplified cRNA was labeled, hybridized, washed, and scanned
according to the manufacturer’s specifications (Affymetrix). The
Affymetrix HG-U133 plus 2.0 GeneChip system was used to
analyze over 54,000 transcripts covering 28473 UniGene clusters.
QUANTITATIVE PCR
The expression levels of transcripts chosen for validation were
determined by multiplexed PCR (TaqMan® Gene Expression
Assays, Applied Biosystems Inc., Foster City, CA, USA). About 18S
ribosomal RNA was utilized as the reference. Samples were ana-
lyzed (Prism® 7900 Sequence Detection System, ABI) according to
manufacturer’s suggested protocols in triplicate. Relative expres-
sion values for each targeted transcript were calculated for each
sample using the comparative CT method. The geometric average
of the mean ratios of each histologic group was calculated along
with the standard error of the mean.
BIOINFORMATICS
The transcript expression data were normalized to a target
intensity of 500 (MAS5.0, Affymetrix). Affymetrix.cel files were
processed with the program GCOS to generate signal values.
Multidimensional scaling (MDS) was performed using one-
correlation as distance metric. Unsupervised hierarchical clus-
tering of samples was performed with Cluster 3.0 and the den-
drograms visualized with Tree View (Eisen Lab, University of
California, Berkeley, CA, USA) Clustering was performed with
the entire gene list (unsupervised) to determine whether there are
groupings of samples and the same software was utilized to gen-
erate heat maps of the most differentially expressed genes. Super-
vised differential gene expression between groups of samples was
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performed using BRB array tools from the National Cancer Insti-
tute (http://linus.nci.nih.gov/BRB-ArrayTools.html). Parametric
p-values are reported and the false discovery rates (FDR) were
calculated using the Benjamini and Hochberg method. The iden-
tification of differentially expressed transcripts was carried out
using MetaCore (GeneGo, San Diego, CA, USA). The raw data
were deposited in GEO (GSE17025).
RESULTS
GENE EXPRESSION ANALYSIS
We assessed the global gene expression patterns of our sam-
ples using unsupervised MDS which revealed two distinct and
homogenous clusters: one comprised of normal endometrium and
the other early stage endometrial cancer including both serous
and endometrioid histotypes (Figure 1). When cancers were ana-
lyzed separately, the histologic subtypes appear to be distinct.
We further examined these differences by identifying differen-
tially expressed genes based on these comparisons. Specifically,
we compared the 79 endometrioid endometrial cancer samples
and 12 serous endometrial cancer samples to 12 normal post-
menopausal endometrial tissue samples to identify statistically
significant differentially regulated transcripts. This comparison
of these early stage cancers with the normal endometrial con-
trols by a univariate t -test revealed differential expression of 6168
transcripts (p< 0.001, FDR< 0.001) indicating that endometrial
cancer cells possess highly distinct transcript profiles compared
to glandular cells from the normal epithelium (Table S1 in Sup-
plementary Material). We further evaluated the expression of six
of these genes [Retinoic Acid Related (RAR) orphan receptor B
(RORB), PEG3, TRH, S100A8, maternal embryonic leucine zipper
kinase (MELK), and DLG7 ] using real-time quantitative PCR to
validate the methodology of our array processing. Quantitative
PCR results were highly consistent with the microarray analysis
(Figure S1 in Supplementary Material). Specifically we included
an analysis of PEG3 and confirmed the altered expression of this
transcript similarly to that we described previously (Risinger et al.,
2003). These analyses indicate that our data quality was high and
reproducible, thus allowing for confidence in the detailed com-
parisons of normal to cancer, low to high grade, non-invasive to
deeply invasive and histotype of cancer that follow.
NORMAL EPITHELIUM TO CANCER
In the comparison of endometrioid endometrial cancers to normal
endometrium, we identified 6583 transcripts that were differen-
tially expressed (p< 0.001, FDR< 0.001%, Table S2 in Supple-
mentary Material). Comparison of serous endometrial cancers
versus controls revealed 4300 differentially expressed transcripts
(p< 0.001, FDR< 0.004%) between the two groups (Figure 2A
and Table S3 in Supplementary Material).
Although these two histotypes of endometrial cancer have
many transcripts that are differentially expressed compared to nor-
mal controls, they also may share a significant proportion of dif-
ferentially expressed transcripts as previously reported (Risinger
et al., 2003). In this analysis, 2582 differentially expressed tran-
scripts were found in association with both histology subtypes
compared to control, with 432 of these transcripts demonstrating
fourfold or greater expression differences.
FIGURE 1 | Unsupervised analysis of stage I endometrial cancers
versus normal post-menopausal endometrium controls (red,
endometrial cancer; blue, normal endometrium controls).
Given the unbalanced number of endometrioid endometrial
cancers in this sample set, we further refined our comparisons to
normal by selecting a set of 12 endometrioid endometrial cancers
closely matched by sub-stage and grade to the serous endome-
trial cancers. Using these balanced sets of cases, the comparison of
endometrioid cancer to normal identified about 5500 differentially
expressed transcripts (p< 0.001). A comparison of the differential
expressions between the histotypes assessed by matched sample
sizes reveals common and distinct transcripts (Figure 2B). Fur-
thermore, when these data were analyzed by MDS all three types of
samples were distinctly clustered confirming the validity of gross
differences between the two histotypes irrespective of the large
number of endometrioid cases. Because these selected endometri-
oid cases were matched to serous in terms of grade it also strongly
suggests that these distinctions are maintained even between high
grade endometrioid and serous carcinoma.
TRANSCRIPT EXPRESSION AND TUMOR GRADE
To understand if distinct transcript expression changes associ-
ated with tumor grade exist, an unsupervised MDS analysis of
grade in the endometrial cancer samples was performed to identify
changes in transcript expression associated with poorly differenti-
ated tumors. When the entire sample set was evaluated, including
both serous and endometrioid cancers, the grade three endometri-
oid cancers did not appear to segregate with the serous tumors
(grade 3 by definition) Because serous cancers were shown to
be different compared to endometrioid tumors we conducted a
focused analysis of transcript expression levels as a function of
grade in endometrioid endometrial cancer (grade 1, n= 30 versus
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FIGURE 2 | (A) Venn diagrams showing relationship between serous and
endometrioid endometrial cancers in terms of the differentially expressed
genes (p<0.001) that are unique and shared among histologic subtypes
when compared to normal endometrium. (B) Heat map of differentially
expressed transcripts in matched analysis of endometrioid, serous, and
normal tissues.
grade 3, n= 13). Although an unsupervised MDS analysis indi-
cated no distinct clustering according to grade (data not shown),
a supervised differential expression analysis resulted in identifica-
tion of 498 statistically significant (p< 0.001, FDR< 0.1) differ-
entially abundant transcripts (Tables S1 and S4 in Supplementary
Material).
EFFECT OF MYOMETRIAL INVASION
To address whether depth of invasion is the result of biologic
differences between cancers or simply a reflection of the tem-
poral progression of disease, we analyzed the gene expression of
endometrioid cases with no myometrial invasion (n= 30) against
those that were deeply invasive (n= 23). In 2010, FIGO updated
endometrial cancer staging to reflect in part the relative lack of
prognostic difference between the previous stage IA and stage IB
sub stages using 1988 FIGO staging criteria. Despite these clin-
ical data, we chose to compare only the extremes of invasion
(superficial IA to deeply invasive IC). Unsupervised MDS analysis
indicated no separation of stage IA cancers versus stage IC cases
(data not shown) suggesting that depth of invasion is not reflected
in a global transcript expression pattern. Univariate t -tests indi-
cated only 46 transcripts (p< 0.001, FDR 0.9) which may be found
merely by random chance.
VALIDATION OF SELECTED GENES IN INDEPENDENT SAMPLE SETS
Four transcripts [RORB, Indian Hedgehog gene (IHH ), DLG7
(DLGAP5), and MELK ] whose expression levels were identified as
altered by hybridization-based microarray analysis in the discovery
set were chosen for validation in an external sample set com-
prised of 58 endometrial cancer (40 endometrioid and 18 serous)
and 25 normal endometrial (7 post-menopausal and 18 pre-
menopausal) tissue specimens utilizing by qRT-PCR (Figure 3).
Specifically RORB expression was highly down-regulated in can-
cers including both serous and endometrioid types. DLG7 and
MELK were up-regulated in cancers compared to normal endome-
trial specimens and more highly in serous cancer as compared to
endometrioid cancer. We also confirmed the serous cancer-specific
down-regulation of IHH. Expression of IHH and its association
with tumor grade is shown in Figure 4.
BIOLOGICAL CLASSIFICATION OF DIFFERENTIALLY EXPRESSED GENES
We investigated whether certain cellular pathways are dysreg-
ulated in early stage cancer. A comparison of the endome-
trial cancers (serous and endometrioid) versus normal post-
menopausal endometrium control gene list using the MetaCore
(GeneGo) pathway and ontology mining database revealed enrich-
ment of pathways involved in cell cycle, cytoskeletal remodel-
ing, chemokines in cell adhesion, and several signaling pathways
including PTEN, Wnt, Flt, and CREB (Figure 5). In order to deter-
mine if the transcripts identified in this study were mostly reflective
of a “proliferation signature of cancer,” we also evaluated array
data from a comparison of 91 stage I cancers to laser microdis-
sected epithelium from a separate set of 6 pre-menopausal women
(Table S5 in Supplementary Material). Comparisons of ontology
results between the cancers versus post-menopausal controls and
the cancers versus pre-menopausal controls revealed that cell cycle
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FIGURE 3 | Quantitative PCR of four selected transcripts performed on
an independent set of endometrial tissues to include stage I serous (S)
and endometrioid (E) cancers, normal post menopausal epithelium
(N), proliferative epithelium (Pr), and secretory epithelium (Se).
and cell division ontologies were still the most significant ontolo-
gies resultant from pathway analysis of the differentially expressed
genes (data not shown).
DISCUSSION
In this study, we examined the transcript expression profiles of
stage I endometrial cancers and post-menopausal epithelium to
gain insight into the biology and to determine the relevance of
expression profile differences to clinical and pathologic variables
used to characterize this disease. Although several investigations
have previously examined gene expression profiles associated with
different subtypes of endometrial cancer, few have been designed
specifically to identify transcripts that are differentially expressed
between endometrial cancer and normal endometrium, and none
have examined the effect of sub-stage on transcript expression. We
selected a heterogeneous group of stage I endometrial cancers on
the basis of grade and degree of myometrial invasion representing
the full range of stage I sub-strata.
Two previous study performed comparisons of normal post-
menopausal samples with serous and endometrioid cancers
(Risinger et al., 2003). Our previous study consisted of only 7 nor-
mal specimens compared to 39 endometrial cancers (including 6
serous and 11 endometrioid stage I cancers) limiting the power of
performing stratified analyses. Similarly the only other large study
of microdissected normal endometrium and endometrial cancer
did not analyze their data based on stage I sub-stage criteria nor are
these data publicly available to perform such comparisons (Wong
et al., 2007).
The present study of endometrial cancer gene expression dif-
fered from most prior studies in the selection of normal control
specimens (Mutter et al., 2001; Saidi et al., 2004; Wong et al.,
2007). We chose to examine normal endometria exclusively from
post-menopausal women since the vast majority of endometrioid
and almost all serous endometrial cancers occur after menopause.
Although we did not have clinical data to reflect which of these
women might have been on hormone replacement therapy, each
normal endometrial specimen was reviewed prior to inclusion to
confirm an atrophic post-menopausal pattern. The choice of what
constitutes a “normal control” for endometrial cancer is problem-
atic. While serous cancers are thought to develop from atrophic
endometrium, some endometrioid cancers may occur in obese
individuals who may have a post-menopausal endometrium that is
stimulated in part by their weight-related estrogenic milieu. About
20% of women develop endometrial cancer prior to menopause.
Approximately half of the endometrial cancers in this study were
from post-menopausal women who were considered to be normal
weight. Our choice of age matched, yet atrophic, endometrium
might be postulated to enhance the discovery of transcripts related
to cell division. Analysis of Gene Ontology (GO) does indeed iden-
tify cell proliferation and apoptosis as some of the most important
ontologies (Figure 5). To determine if the transcripts identified in
this study were mostly reflective of a “proliferation signature,” we
also compared these same stage I cancers to laser microdissected
epithelium from a separate set of array data obtained from pre-
menopausal women. Even in this comparison, cell cycle and cell
division are the most significant ontologies resultant from pathway
analysis of significant genes. This additional comparison suggests
that gene expression changes related to these processes in cancer
predominates over the menopausal status of the normal control.
Although serous and endometrioid stage I endometrial cancers
share many differentially expressed genes when compared to nor-
mal controls, they are distinctly different from one another, a find-
ing we and others have previously reported (Risinger et al., 2003;
Maxwell et al., 2005; Zorn et al., 2005). These previous analyses did
not include significant numbers of stage I serous cancers to deter-
mine whether these are a distinct subtype. In the set of transcripts
that we sought to validate, we specifically selected some molecules
that were significantly different among endometrioid and serous
carcinomas compared to normal endometrium. Among these, we
found that two previously implicated stem cell associated mark-
ers, the disks large homolog 7 (DLG7, also known as DLGAP5)
and the maternal embryonic leucine zipper kinase MELK tran-
scripts were elevated in endometrial cancer specimens compared
to controls. Recently MELK has been described as over-expressed
in carcinomas and in particular their stem cell niche (Risinger
et al., 2003; Liu et al., 2006; Marie et al., 2008; Nakano et al., 2008;
Pickard et al., 2009). The exact function of theMELK gene product
(MELK) in normal and tumor biology remains to be determined.
The identification of up-regulated MELK has the potential to be
exploited clinically if a tumor growth phenotype is attributed to
MELK, as kinases have often been effectively targeted by small mol-
ecule therapy in cancer. Similarly the DLG7 gene product (DLG7)
is associated with several malignancies (Chiu et al., 2002; Tsou
et al., 2003; Gudmundsson et al., 2007). Furthermore DLG7 may
be directly involved in cell transformation (Yu et al., 2005). Given
that over-expression of these two genes was more prominent in
serous versus endometrioid cancers, our findings could suggest
that the resistance of serous cancers to contemporary therapy may
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FIGURE 4 | Expression of IHH in all endometrial cancer samples according to tumor grade.
be in part due to an increased prominence of tumor cell progeni-
tors within these cancers or reflect a more aggressive proliferative
lesion. Based on these findings, further investigation is warranted
in identifying the functions of these two genes in endometrial
cancer.
Among the validated differentially expressed transcripts, the
IHH was noted to be highly down-regulated in serous cancers.
The IHH gene product (IHH) has been extensively studied in
the uterus and is a key signaling molecule in regulation of the
uterine epithelium in preparation for implantation (Lee et al.,
2006; Franco et al., 2010). Furthermore, IHH expression is reg-
ulated by ovarian steroids, and signaling occurs through progestin
and surrounding stroma (Simon et al., 2009). Our validation data
also revealed the significant up-regulation of IHH in the pro-
liferative endometrial epithelium consistent with other mRNA
studies on normal uterine samples sampled throughout the men-
strual phase (Talbi et al., 2006). Decreased IHH expression has
also been described in endometriosis (Smith et al., 2011). Our
array discovery- and qRT-PCR-based validation data indicated
a stark reduction of expression in the serous cancers and in
some endometrioid cancers. Importantly we also noted the pres-
ence of IHH on our list of differentially expressed transcripts
related to tumor grade. Specifically IHH was distinctly down-
regulated in most high grade cancers regardless of histotype
(Figure 4). Poorly differentiated endometrial cancers are more
frequently associated with lack of expression of the estrogen and
progesterone receptor. We further explored this by examining
PGR mRNA levels in these cancers and found that loss of PGR
and IHH expression were correlated. Despite its importance in
normal uterine biology, the Hedgehog pathway has not been
extensively investigated in uterine carcinoma. Given the role of
IHH in negatively regulating the Hedgehog signaling pathway,
these data suggest that some high grade endometrial cancers
might benefit from targeted Hedgehog pathway intervention.
Down-regulation of the nuclear orphan receptor RORB, a
receptor that is part of the NR1 nuclear receptor family, was
one of the most strikingly down-regulated transcripts in both
serous and endometrioid cancer. We noted robust expression
in both pre- and post-menopausal endometrium controls. Since
expression was markedly higher in secretory compared to pro-
liferative endometrium, the loss of RORB expression may be
related to endometrial differentiation, a process known to be
mediated in part by retinoic acid (a ligand for RORB) (Stehlin-
Gaon et al., 2003). Retinoic acid has a long known function
in modulating steroid driven proliferation and differentiation
responses in the uterus as well as modulating carcinogenesis
(Siddiqui et al., 1994; Loughney et al., 1995; Brar et al., 1996;
Li et al., 2002, 2005; Cheng et al., 2011). The loss of RORB
expression in endometrial cancer warrants further investigation.
In the comparing normal post-menopausal to cancer sub-
types, we noted differentially expressed transcripts common to
both serous and endometrioid endometrial cancers, many of
which could be considered as targets for preventive or therapeu-
tic regimens (Tables S2 and S3 in Supplementary Material). For
example, the TPX2 gene encodes an Aurora kinase A-stimulated
microtubule regulating molecule that when over-expressed in
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FIGURE 5 | Genes differentially expressed in early stage
endometrial samples compared to normal epithelia were
evaluated for enrichment of biologic pathways using the
MetaCore (GeneGo) analysis tool. A histogram of log p-values is
shown; the list is arranged in descending order with the most
significant pathways at the top.
cancer is associated with tumorigenesis (Scharer et al., 2008;
Warner et al., 2009). In addition, specific targeting of TPX2
with short interfering RNAs in pancreas cancer cells results
in decreased proliferation and tumorigenicity. Cancer cells in
which TPX2 levels have been suppressed by small interfering
RNAs are more sensitive to the microtubule stabilizing can-
cer drug paclitaxel (Warner et al., 2009). Similarly, disrupting
Aurora kinase activity sensitizes ovary cancer cells to pacli-
taxel (Scharer et al., 2008). Both DLGAP5 and TPX2 appear
to rely on increased Aurora kinase function. Estrogen induced
www.frontiersin.org June 2013 | Volume 3 | Article 139 | 7
Risinger et al. Transcriptomic analysis of endometrial cancer
tumors in hamsters overexpressing Aurora kinase develop uter-
ine like stem cell tumors in their kidneys. It is possible
that uncontrolled estrogenic stimulus in endometrial cells is
mediated in part through Aurora kinases which are active in
endometrial cancers (Kurai et al., 2005). Although many stage
I endometrial cancers are cured by surgery alone, those that
recur have very poor prognosis with limited treatment options.
Investigation of Aurora kinases and/or TPX2 targeted thera-
pies should be considered in “high risk” early stage cancers.
The loss of cell polarity and normal cell adhesion processes
are central features of cellular transformation and metastasis.
We noted a distinct enrichment for dysregulated genes in the
cell adhesion (tetraspanins and integrin) pathway by GeneGo
analysis of all of the differentially expressed genes. Although
members of the integrins and tetraspanins have been exam-
ined in endometrial cancer there has not been focused study
for many of these key molecules in early disease. Our data
show that signaling through deregulated integrin and tetraspanins
may account for the observed increased expression of focal
adhesion kinase (FAK) and ezrin in this endometrial cancer
data set. FAK is a central component regulating invasion and
metastasis and limited data suggest it is up-regulated at the
protein level in some endometrial carcinomas (Livasy et al.,
2004). Similarly, increased expression of the cytoskeletal link-
ing protein ezrin is seen in endometrial hyperplasia and car-
cinoma (Ohtani et al., 1999, 2002; Kobel et al., 2006). In
stage I endometrial cancers, ezrin expression was also linked
to poorer prognosis (Kobel et al., 2006). Our network data
suggests additional linkages related to these signaling path-
ways and is depicted in Figure S1 in Supplementary Material.
Our data showed the absence of statistically significant
differentially expressed genes associated with deep myome-
trial invasion, a poor prognostic factor associated with
an increased risk of extra-uterine metastasis. A dogmatic
theme in molecular carcinogenesis is the progressive accu-
mulation of genetic defects as cells progress from nor-
mal cells to premalignant cells to carcinomas. Most inter-
estingly our study found few genes with expression changes
of statistical significance between non-invading and deeply
invaded stage I endometrial cancers. These data suggest that
a large component of endometrial cancer progression may
be temporal and not due to further accumulation of cel-
lular defects reflective in gene expression. LKB1 previously
implicated in endometrial cancer invasion (26), was not
among the few differentially expressed genes identified.
In summary, we determined that stage I endometrial can-
cers have unique global expression patterns based on their his-
tologic subtype. However, this study importantly describes a
large number of gene transcripts that are distinctly dysregu-
lated regardless of histotype when these cancers are compared
to normal endometrial epithelium. Most surprising was the dis-
tinct lack of changes that existed between superficially invasive
stage I cancers when compared to those that are deeply inva-
sive, which suggests that depth of invasion may have a tem-
poral etiology and does not necessarily reflect a unique bio-
logical expression profile that develops as an endometrial can-
cer becomes more advanced. Future studies aimed at identify-
ing effective prognostics for predicting stage I cancer recurrence
will likely have to focus away from the traditional clinical and
pathologic criteria in order to be effective. Given that many
early stage endometrial cancers share significant common gene
expression changes, broad-based preventive and chemotherapeu-
tic strategies have the potential to be developed that impact both
endometrioid and serous subtypes of endometrial carcinoma.
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